Cephalexin, 7 -(D -a -amino -a -phenylacetamino)-3-methyl-3-cephem -4-carboxylic acid, is quite similar structurally to cephaloglycin, differing only in the removal of an acetoxy group (Fig. 1) . This change has resulted in almost complete absorption from the gastrointestinal tract (4, 7) . In contrast, the parent cephaloglycin is poorly absorbed. Cephalexin is excreted in active form in the urine. Urine concentrations of cephalexin many fold greater than the concentrations in serum can be achieved (7) . Most strains of Escherichia coli, Proteus mirabilis, and Klebsiella (all frequent urinary tract pathogens) are inhibited by the increased concentration of cephalexin in the urine (6) .
The present study was undertaken to determine the urine and serum concentrations of cephalexin in patients with impaired renal function and to evaluate the efficacy of hemodialysis in lowering the concentrations in serum in the anephric patient. In addition, a number of patients with renal transplants who had urinary tract infections were studied.
MATERIALS AND METHODS Antibiotics. Cephalexin, supplied in powdered form (Eli Lilly Co., Indianapolis, Ind.), was freshly diluted in phosphate-buffered saline (pH 7.0) and used in all assay procedures. Volunteer subjects and patients were given 250-or 500-mg doses of cephalexin in gelatin capsules.
In vitro tests. Blood obtained from patients was allowed to clot, and the serum was harvested and stored at -20 C until assayed by the cylinder cup method of Grove and Randall (2) Absorption and renal excretion of cephalexin in patients with impaired renal function. Three patients with endogenous creatinine clearances ranging from 18 to 40 ml/min were given 250 or 500 mg of cephalexin after an overnight fast (Table  1) . Peak serum levels were just slightly higher than those of normal controls. However, a much slower decline in the serum levels of cephalexin was observed so that at 12 hr, and in one patient (G.S.) at 24 hr, an appreciable concentration of cephalexin remained. The concentration of cephalexin in urine collected over the first 8 hr ranged from 50 to 400 ,ug/ml and paralleled the endogenous creatinine clearance.
Serum levels of cephalexin in the anephric patient and effect of hemodialysis. Peak serum levels in the anephric patient were seen in 1 hr after oral administration (Fig. 2) . After a short, rapid fall in the 2nd hr, the serum level remained elevated over the next 12 hr. In two patients, whose serum concentration of cephalexin 2 hr after oral ingestion was 4.5 and 4.3 Ag/ml, peak levels of 17 and 11 ,ug/ml were reached at 6 and 12 hr, respectively. This accounted for the small secondary rise in the mean concentration of cephalexin in the group as a whole seen at 6 and 12 hr.
Hemodialysis proved to be an efficient procedure in lowering the serum cephalexin concentration. The mean predialysis concentration of cephalexin in the six anephric patients was 9.6 Ag/ml (range, 5.5 to 17.5 jig/ml). After 6 hr of dialysis, this had been lowered to-4.0 ,ug/ml (range, 3.0 to 5.2,ug/ml), a mean reduction of 58%. Akhough dialysis was usually carried out for 8 hr, only two These showed a reduction of 60 and 62%-~from the predialysis levels. Clinical trial of cephalexin in patients with chronic urinary tract infections. All five patients studied had a functioning renal transplant and were receiving corticosteroids and azathioprine at the time of antibiotic therapy. In addition, most had relapsed or had not responded to previous antibiotic regimens. Cephalexin (250 mg, four times a day) was administered for 11 to 150 days ( Table 2 ). Two of the five patients received a second course of cephalexin therapy. In only two of the five patients was the urine sterile 1 month after initial therapy was discontinued. The urine of a third patient (P.M.) was sterile 1 month after a second course of cephalexin was extended for 150 days. Failure to eradicate the original organism, relapse with the same organism, or superinfection were encountered after the first course of cephalexin therapy in three of the five patients.
DISCUSSION
Cephalexin is a new semisynthetic cephalosporin derivative with an antibacterial spectrum similar to cephalothin and cephaloridine (4, 6) . Given by mouth, cephalexin was found to be absorbed well by healthy volunteers. Kind and coworkers (4) (3) .
In only two of five renal transplant patients with chronic urinary tract infections was the urine sterile 1 month after discontinuing cephalexin therapy. Superinfection with another organism, relapse, or persistance of the same organism were all observed. Similar results in the treatment of urinary tract infections have been previously reported (1, 6). The drug was well tolerated by all patients, and no renal toxicity was noted.
Cephalexin appears to be a useful addition to the antibiotics currently available. It is absorbed well from the gastrointestinal tract and rapidly excreted by the kidneys. The resulting high urine concentrations of the drug, even in the patients with impaired renal function, are adequate for the treatment of many common urinary tract pathogens. So far, serious nephrotoxicity has not been reported.
